Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06828055 · ClinicalTrials.gov registry record · Phase 2
VK2735 for Weight Management Phase 2 (Venture Oral Dosing)
A Phase 2 study of Weight Loss, sponsored by Viking Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 280
- Enrollment target
- 15
- Study locations
NCT06828055 is a Phase 2 study of Weight Loss that has completed, run by Viking Therapeutics. The registered enrollment target is 280 participants, below the 1,499-participant average among 116 other Weight Loss trials with a reported enrollment target (81% lower). The trial reports 15 study locations across 10 states.
The verdict
NCT06828055, a Phase 2 study of Weight Loss, has completed, sponsored by Viking Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 280 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 Oral Formulation in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. VK2735 or matched placebo will be administered once daily.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VK2735
Study Locations (15)
Florida
- Viking Clinical Site #101 - Clearwater
- Viking Clinical Site #108 - Largo
- Viking Clinical Site #107 - Ocoee
- Viking Clinical Site #102 - Port Orange
Missouri
- Viking Clinical Site #109 - City of Saint Peters
- Viking Clinical Site #112 - Kansas City
Texas
- Viking Clinical Site #104 - Austin
- Viking Clinical Site #106 - San Antonio
Arizona
- Viking Clinical Site #111 - Peoria
California
- Viking Clinical Site #105 - Lake Forest
Indiana
- Viking Clinical Site #100 - Indianapolis
Kentucky
- Viking Clinical Site #110 - Louisville
Louisiana
- Viking Clinical Site #114 - Marrero
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2024-12-18 |
| Est. Completion | 2025-08-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06828055
The ClinicalTrials.gov registry entry for NCT06828055 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,499-participant average among 116 other Weight Loss trials with a reported enrollment target (81% lower). The listed sponsor is Viking Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Weight Loss appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06828055 reports 15 study locations spanning 10 distinct geographic areas - top geographies include Florida, Missouri, Texas.
Frequently Asked Questions
What is clinical trial NCT06828055 about?
NCT06828055 is a clinical study titled "VK2735 for Weight Management Phase 2 (Venture Oral Dosing)". This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 Oral Formulation in adults who are obese (BMI ≥30 kg/m2) or who are over...
What is the current status of trial NCT06828055?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 280 participants. The study started on 2024-12-18. Estimated completion is 2025-08-15.
What conditions does trial NCT06828055 study?
This clinical trial studies the following conditions: Weight Loss.
What interventions are being tested in trial NCT06828055?
The interventions under investigation include: Placebo (DRUG), VK2735 (DRUG).
Who is sponsoring clinical trial NCT06828055?
This trial is sponsored by Viking Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06828055 being conducted?
This trial has 15 study locations across Arizona, California, Florida, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Weight Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fasted vs. Fed State Exercise
RECRUITING · Phase 2
-
Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
RECRUITING · Phase 2
-
Effectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational Diabetes
RECRUITING · Phase 2
-
Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults
RECRUITING · Phase 2
-
Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
RECRUITING · Phase 2
-
Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid Tumors
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.